← Back to Home

Detecting Signs of Drug Resistance Before Breast Cancer Progresses: Guardant360 CDx Receives European CE Marking

Blood-based monitoring of tumor mutations is bringing forward the timing of treatment switches for some patients with advanced breast cancer. This companion diagnostic can help identify patients suitable for camizestrant; clinical trials support delaying disease progression, but an overall survival benefit remains uncertain.

By SURL BioNews

During treatment for advanced breast cancer, molecular signs of drug resistance may emerge even before tumors show progression on imaging. Detecting these changes early in the blood could give physicians an opportunity to adjust treatment before the disease progresses. On October 8, Guardant Health announced that its liquid biopsy test, Guardant360 CDx, had received CE marking under the European In Vitro Diagnostic Medical Devices Regulation (IVDR) for use as a companion diagnostic for camizestrant, helping identify patients who may benefit.

This use is intended for estrogen receptor–positive (ER-positive), HER2-negative locally advanced or metastatic breast cancer. The test analyzes tumor-derived DNA in a blood sample to look for ESR1 mutations. The role of a companion diagnostic is to link specific molecular changes to drug selection, providing an additional basis for treatment decisions.

ESR1 mutations are one of the key mechanisms of resistance to endocrine therapy in this type of breast cancer. Camizestrant is an oral selective estrogen receptor degrader that acts on the receptor supporting tumor growth. AstraZeneca announced in July of this year that the drug, in combination with a CDK4/6 inhibitor, had been approved in the European Union for adult patients who develop ESR1 mutations during first-line endocrine combination therapy but whose disease has not yet progressed. The test’s CE marking further addresses the diagnostic step needed to identify these patients.

An October 9 report by OncLive noted that the clinical evidence for this early treatment-switching strategy comes from the phase 3 SERENA-6 trial. The study monitored circulating tumor DNA every two to three months alongside routine imaging and randomized 315 patients who had developed ESR1 mutations but had no progression on imaging: one group switched from an aromatase inhibitor to camizestrant, while the other continued its existing treatment. Both groups maintained the same CDK4/6 inhibitor.

In the trial’s initial analysis, median progression-free survival was 16.0 months in the group that switched to camizestrant and 9.2 months in the group that continued an aromatase inhibitor. This finding supports the use of blood-based mutation signals to switch endocrine drugs early in selected patients to delay disease progression. However, these figures reflect the effect of the entire monitoring and treatment strategy and cannot be taken as a direct measure of the test’s accuracy. They also do not mean that every patient will receive the same magnitude of benefit.

The limits of the benefit still need to be made clear: overall survival data are currently immature, and delayed progression cannot be directly interpreted as a proven extension of life. Guardant’s announcement also did not provide the test’s sensitivity for this use, guidance on interpreting negative results, or country-specific reimbursement and access arrangements. CE marking provides an additional regulatory basis for bringing molecular monitoring into clinical use; the ability to complete testing, interpret results, and connect patients with treatment promptly in routine care remains key to implementing this strategy.

References

  1. Guardant Health
  2. OncLive